Details for Patent: 12,268,666

Which drugs does patent 12,268,666 protect, and when does it expire?

Patent 12,268,666 protects JAYPIRCA and is included in one NDA.

This patent has twenty-three patent family members in seven countries.

Summary for Patent: 12,268,666

Title:	Spray-dried dispersions, formulations, and polymorphs of (S)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1H-pyrazole-4-carboxamide
Abstract:	A spray-dried dispersions and pharmaceutical composition of (S)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1H-pyrazole-4-carboxamide, pharmaceutically acceptable salts thereof, or a combination thereof and the use of the spray-dried dispersion and pharmaceutical composition in the treatment of cancer and autoimmune and inflammatory diseases are disclosed. Also provided are crystalline forms of (S)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1H-pyrazole-4-carboxamide also useful in the treatment of cancer and autoimmune and inflammatory diseases.
Inventor(s):	Barbara J. Brandhuber, Lauren T. Brent, Charles Todd Eary, Andrew Kenna, Firas Khan, Vivian F. H. Renshaw, Stacey Renee Spencer
Assignee:	Loxo Oncology Inc
Application Number:	US18/440,563
Patent Claim Types: see list of patent claims	Compound;

Drugs Protected by US Patent 12,268,666

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Loxo Oncol	JAYPIRCA	pirtobrutinib	TABLET;ORAL	216059-001	Jan 27, 2023		RX	Yes	No	12,268,666		Y
Loxo Oncol	JAYPIRCA	pirtobrutinib	TABLET;ORAL	216059-002	Jan 27, 2023		RX	Yes	Yes	12,268,666		Y

International Family Members for US Patent 12,268,666

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2019314302
Australia	2022259781
Australia	2022275440
Canada	3108065
Canada	3224945
Canada	3224949